DFTX — Definium Therapeutics Share News
0.000.00%
Last trade - 00:00Psychedelic drug developers rise after Trump signals regulatory support
Brief: Definium Therapeutics Supports White House Executive Order On Mental Health Innovation, Committed To Developing Psychedelic Treatments For Mental Health
U.S. RESEARCH ROUNDUP-Chevron, Littelfuse, Parker-Hannifin
LSD therapy biotech Definium sued for alleged trade secret theft
U.S. RESEARCH ROUNDUP-Definium Therapeutics, Kenvue, Werner Enterprises
Brief: Definium Therapeutics Appoints Roger Adsett To Board Of Directors
MindMed Q3 net loss widens to $67.3 mln
Brief: MindMed Q3 Net Income USD -67.265 Million
U.S. STOCKS ON THE MOVE-Fiserv, CMS Energy, Moderna
U.S. STOCKS ON THE MOVE-Wolfspeed, Carvana, Metsera
MindMed dips after $225 mln stock deal
Brief: Mind Medicine Says It Announces Pricing Of $225 Million Public Offering At $12.25 Per Share
Mind Medicine (MindMed) Inc reports results for the quarter ended June 30 - Earnings Summary
MindMed Q2 net loss widens to $42.7 mln, R&D costs rise
Brief: Mindmed Strengthens Executive Team With Appointment Of Brandi Roberts As Chief Financial Officer
Mind Medicine (MindMed) Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Mind Medicine (Mindmed) Inc - Mindmed Enters Into First Amendment To Loan And Security Agreement - SEC Filing
Brief: Mindmed Announces First Patient Dosed In Phase 3 Emerge Study Of Mm120 In Major Depressive Disorder (Mdd)
Mind Medicine (MindMed) Inc reports results for the quarter ended December 31 - Earnings Summary